Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
in response toby
A point worth mentioning is that they are both antibodies that have to be given by injection every two weeks or so. Are such therapies likely to compete effectively in the market place with a tablet? I can envisage injections being commercially successful to treat advanced dementia but to be given to hundreds of thousands of cases of mild dementia? I wonder.
If it’s effective, ABL would have a much bigger market imo.